This site uses cookies. By continuing to browse the site without disabling them, you consent to our use of cookies. To learn more about the types of cookies we use, please view our cookie policy.

Indivior
  • Product Query or Adverse Event
  • Careers
  • Contact Us
  • Locations
  • International
  • About
    • History
    • Leadership
  • Diseases of Addiction
    • A Worldwide Crisis
    • The Patient Journey
  • R & D
    • Publications
    • White Papers
    • Abstracts
    • Grants
  • Products
  • Responsibility
    • Environment, Climate Change and Health and Safety
    • Communities
    • Patient Safety and Product Quality
    • Business Conduct
    • People
    • Advocacy and Stakeholder Engagement
  • Investors
  • Media
  • Investor Information
    • Annual Reports
    • Press Releases
    • RNS Filings
    • RNS Filings (Inside Information)
    • SEC Filings
    • Corporate Alert Service
    • Webcasts / Audiocasts / Presentations
    • Prospectus
    • Upcoming Events
    • Buprenorphine Market Modeling Methodology
  • Share Price
    • Share Price Center
    • Share Price Table
    • Historic Share Price
    • Share Price Calculator
    • Demerger: Base Cost
  • Corporate Governance
    • UK Corporate Governance Code
    • Leadership
    • The Board
    • Board Committees
    • Executive Committees
    • Risk Management and Internal Control
    • Indivior Integrity & Compliance Program
    • Integrity & Compliance
    • Corporate Responsibility
    • Tax Strategy
    • Global Conduct Policies
  • Shareholder Information
    • Managing Your Shareholding
    • Dividends
    • Annual General Meeting
    • American Depositary Receipts
  • Contact Us
  • Investor Information
    • Annual Reports
    • Press Releases
    • RNS Filings
    • RNS Filings (Inside Information)
    • SEC Filings
    • Corporate Alert Service
    • Webcasts / Audiocasts / Presentations
    • Prospectus
    • Upcoming Events
    • Buprenorphine Market Modeling Methodology
  • Share Price Information
    • Share Price Center
    • Share Price Table
    • Historic Share Price
    • Share Price Calculator
    • Demerger: Base Cost
  • Corporate Governance
    • UK Corporate Governance Code
    • Leadership
    • The Board
    • Board Committees
    • Executive Committees
    • Risk Management and Internal Control
    • Integrity & Compliance
    • Corporate Responsibility
    • Tax Strategy
    • Global Conduct Policies
  • Shareholder Information
    • Managing Your Shareholding
    • Dividends
    • Annual General Meeting
    • American Depositary Receipts
  • Contact Us

RNS Filings (Inside Information)

October 15, 2019 – Indivior Raises FY 2019 Net Revenue and Net Income Guidance

July 11, 2019 – Indivior Raises FY 2019 Net Revenue and Net Income Guidance; Cash at H1 2019 Expected to be Approximately $985m

May 02, 2019 – Indivior PLC Q1 2019 Financial Results

Feb 14, 2019 – Indivior PLC FY 2018 Financial Results

Sep 26, 2018 – Indivior Provides Update on Key Business Drivers and Expectations

July 25, 2018 – Indivior H1 2018 Financial Results

July 11, 2018 – Indivior Sees FY18 Guidance Below Expectations

Mar 23, 2018 – Indivior Responds To Court Ruling in ANDA Litigation and Announces Intention To Appeal

Feb 15, 2018 – Indivior PLC Full Year 2017 Financial Results

Feb 1, 2018 – Indivior Provides Updates on Tax Position

Nov 30, 2017 – SUBLOCADE FDA Approval Press Release

Nov 30, 2017 – SUBLOCADE Fact Sheet

Sep 1, 2017 – Indivior Responds To Court Rulings in ANDA Litigation and Announces Intention To Appeal

July 27, 2017 – Indivior Half Year Financial Results

March 13, 2017 – Indivior RBP-7000 Top-line Results

February 22, 2017 – Indivior PLC FY 2016 Financial Results

November 2, 2016 – Nine Month Financial Results: Litigation Provision of $220m booked: Guidance raised

August 17, 2016 – RBP-6000 Phase 3 Top Line Results

July 29, 2016 – Indivior Half Year Financial Results

  • About
  • Diseases of Addiction
  • R & D
  • Products
  • Responsibility
  • Investors
  • Media
  • MODERN SLAVERY STATEMENT (PDF)
  • Product Query or Adverse Event
  • Careers
  • Contact
  • Terms of Use
  • Privacy Policy
  • Accessibility
  • International

© 2018 Indivior PLC | This site is intended for US audiences. | INDIVIOR is a registered trademark of Indivior UK Limited.

You are now leaving Indivior.com to visit Suboxone.com a US product site intended for US residents and healthcare professionals.

Continue    Return

You are now leaving Indivior.com.

Continue    Return